Drug intelligence / Profile preview

SygeLIX-Coll-T

Development stage: Phase 1
Lead developer: TBF Génie Tissulaire
Modality: Cell Therapies
Administration: Ophthalmic, Topical

Overview

SygeLIX-Coll-T is an investigational ophthalmic biologic developed by TBF Génie Tissulaire for the treatment of chronic keratitis and corneal ulcers. It is a reconstituted suspension composed of trehalose and Wharton's jelly extract, a primordial mucous connective tissue derived from the umbilical cord. The extract is rich in mesenchymal stem cells (MSCs), growth factors, cytokines, hyaluronic acid, and extracellular vesicles, which provide anti-inflammatory, pro-healing, and regenerative effects on the corneal epithelium. The product is currently being evaluated in a Phase 1 clinical trial (NCT05200000) for patients with chronic keratitis refractory to standard therapies.

Other names: Wharton's jelly extractWharton's Jelly Extract Eye Drops

Beyond the preview

Go deeper on SygeLIX-Coll-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SygeLIX-Coll-T.

Explore the full profile